Keywords: Merkel cell; Merkel cell carcinoma; PD-1; chemotherapy; hyperprogressive disease; immunotherapy; medical dermatology; metastatic; nonmelanoma skin cancer; paradoxical reaction; pembrolizumab; skin cancer; squamous cell carcinoma.